However, in Turkey, the frequency of ILD development related explicitly to CDK4/6 inhibitors used in breast cancer, the impact of different CDK4/6 inhibitor molecules, and additional risk factors contributing to this frequency have not yet been identified. The gene discussed is CDK4; the disease is interstitial lung disease.